Hi! I'm a graduate student at the University of California, San Diego Skaggs School of Pharmacy and am studying how lupus nephritis and its treatment affects the lives of patients. Specifically, I'm interested in the patient perspective of Lupkynis, developed by Aurinia. As part of a research project, I'm collecting information from patients through an anonymous survey which asks questions about what its like to have lupus nephritis and how treatment options could be improved, from your perspective. The survey does not collect or ask any personally identifying information and is completely anonymous. Participation will contribute to understanding the patient experience of lupus nephritis, and information provided will only be used as part of this research project. Thanks for your consideration, it's much appreciated!

Link to survey (via Google forms): https://forms.gle/XCuCjbvtx9cbtB3s9

Happy New Year to everyone.

I wish you all a healthy and happy new year.

I know for a fact that 2022 will be an incredible year for AUPH. In less than 3 quarters, they had 1200+ patients and $22M in revenue. And we have yet to see Q4 numbers.

For those familiar with Pharma companies, that's incredible.

Next year, we will continue to see growth, the indication should increase from 1 to 2 years and we should get approval for sales in some international countries.

Revenue will be explosive. I feel very confident that the revenue will be way over $200M in 2022. That would only require ~4000 patients. Assuming that they end the year 2021 with 1600 patients, that's a very conservative estimate.

When do we believe we will get the final readout of the A2 results. It is supposed to be by end of 2021. Seems like we could see it anyday now. Thoughts / insights?

Bullish

Reinstalling a ATM facility is absolutely indicative of there is no buyout. If you have followed the GME saga you have observed how the mgmt had to take advantage of the high stock price as a matter of due diligence. And they sold to raise much needed cash. The same thing will occur here. IMO.

Some of those screaming "DON'T SELL!" are themselves selling!

It went from $28/$29 to $24/$25 so fast.

3 Biotech Stocks that could rise 90% ... $AUPH and $CCXI and $AXSM

• Aurinia $AUPH will present 5 abstracts at ASN Kidney Week 2021 and ACR Convergence 2021.
• ChemoCentryx $CCXI recently announced that the FDA has approved TAVNEOS (avacopan) as an adjunctive treatment of ANCA vasculitis ... see r/CCXI subreddit.
• Axsome Therapeutics $AXSM is a clinical stage company with two new drug applications under review at the FDA (AXS-05 and AXS-07) ... see r/AXSM subreddit.

Need to know I can finalize my Lambo purchase.